Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity
- PMID: 2789929
- PMCID: PMC1379955
- DOI: 10.1111/j.1365-2125.1989.tb05437.x
Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity
Abstract
Anti-digoxin antibody fragments (ADAF, 80 mg) were infused intravenously to successfully treat severe digoxin toxicity in an 82 year old woman. During treatment, total and free digoxin were determined using an Abbot TDX analyser and an ultrafiltration technique. ADAF were measured by an enzyme-linked immunosorbent assay. By 1 h after ADAF, total serum digoxin concentrations had risen 12-fold from a pretreatment level of 15.4 nmol l-1 but free digoxin fell from 10 to 0.1 nmol l-1, indicating greater than 99.9% digoxin binding to ADAF. However, the low free levels had rebounded to 7.7 nmol l-1 by 12 h, but despite this rise the patient's condition had improved. A serum ADAF/digoxin molar ratio of around five was associated with the low concentration of free digoxin at 1 h, while at later times with ratios roughly between 3 and 4, the free digoxin concentrations ranged between 2.0 and 7.7 nmol l-1. ADAF were mainly confined to the plasma during the first hour, but subsequently distributed into an apparent volume of 193 ml kg-1. The elimination half-lives of ADAF and total digoxin were 96 and 55 h, respectively. More than 50% of the estimated digoxin load had been excreted in the urine by 5 days; for ADAF the equivalent figure was only about 3%. Renal and/or bacterial degradation may have contributed to the low detection of urinary ADAF.
Similar articles
-
Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.Clin Pharmacokinet. 1995 Jun;28(6):483-93. doi: 10.2165/00003088-199528060-00006. Clin Pharmacokinet. 1995. PMID: 7656506 Review.
-
The plasma kinetics of digoxin-specific Fab fragments and digoxin in the rabbit.J Pharm Pharmacol. 1991 Nov;43(11):807-10. doi: 10.1111/j.2042-7158.1991.tb03488.x. J Pharm Pharmacol. 1991. PMID: 1686913
-
The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit.J Pharm Pharmacol. 1992 Oct;44(10):796-800. doi: 10.1111/j.2042-7158.1992.tb03208.x. J Pharm Pharmacol. 1992. PMID: 1360503
-
Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin.Ann Intern Med. 1993 Aug 15;119(4):273-7. doi: 10.7326/0003-4819-119-4-199308150-00004. Ann Intern Med. 1993. PMID: 8328735
-
Digoxin-specific antibody fragments in the treatment of digoxin toxicity.Clin Toxicol (Phila). 2014 Sep-Oct;52(8):824-36. doi: 10.3109/15563650.2014.943907. Epub 2014 Aug 4. Clin Toxicol (Phila). 2014. PMID: 25089630 Review.
Cited by
-
Fab antibody fragments: some applications in clinical toxicology.Drug Saf. 2004;27(14):1115-33. doi: 10.2165/00002018-200427140-00004. Drug Saf. 2004. PMID: 15554746 Review.
-
Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.Clin Pharmacokinet. 1995 Jun;28(6):483-93. doi: 10.2165/00003088-199528060-00006. Clin Pharmacokinet. 1995. PMID: 7656506 Review.
-
Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.Pharm Res. 1993 May;10(5):692-6. doi: 10.1023/a:1018903614997. Pharm Res. 1993. PMID: 8321833
-
Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.Intensive Care Med. 1992;18(7):439-42. doi: 10.1007/BF01694351. Intensive Care Med. 1992. PMID: 1469187
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources